What do recent guidelines recommend for the management of supraventricular tachycardia (SVT) in adults?

Management of Supraventricular Tachycardia According to Recent Guidelines

For acute SVT management, perform vagal maneuvers first, followed immediately by adenosine if unsuccessful; for ongoing management, catheter ablation should be offered as first-line definitive therapy to most patients, with beta-blockers or calcium channel blockers reserved for those who decline or are not candidates for ablation 1, 2.

Acute Management Algorithm

Step 1: Initial Assessment and Vagal Maneuvers

• Perform vagal maneuvers immediately in all hemodynamically stable patients with regular SVT (Class I recommendation) 2
• The modified Valsalva maneuver achieves 43% conversion rate 3
• Document a 12-lead ECG during tachycardia before conversion to establish the mechanism

Step 2: Pharmacologic Cardioversion

Adenosine remains the drug of choice when vagal maneuvers fail 1, 2:

• Start with 12 mg IV adenosine rather than 6 mg—the higher initial dose achieves 54.2% vs 40.6% conversion (p=0.03) and overall 91% effectiveness 3, 4
• Adenosine has been upgraded to Class I recommendation with stronger evidence 1

Alternative agents if adenosine fails or is contraindicated:

• IV diltiazem or verapamil (Class IIa) 2
• IV beta-blockers (Class IIa) 2
• Critical caveat: Verapamil and diltiazem have been downgraded from previous guidelines and should NOT be used if ventricular pre-excitation is present 1

Step 3: Electrical Cardioversion

• Immediate synchronized cardioversion for hemodynamically unstable patients (hypotension, syncope, myocardial ischemia, severe heart failure) (Class I) 2
• For stable patients, cardioversion is indicated when pharmacologic therapy fails or is contraindicated (Class I) 2
• Recent evidence suggests adenosine may be attempted even in unstable patients before cardioversion (weighted OR 2.41 for ECV success, but adenosine avoids sedation risks) 5

Ongoing Management Algorithm

First-Line: Catheter Ablation

Catheter ablation should be offered as first-line therapy during comprehensive risk-benefit discussion 1, 6:

• Single procedure success rates: 94.3-98.5% 3
• Very low complication rate with modern techniques
• This represents a major shift—ablation is now prioritized over long-term pharmacotherapy 1, 6

Second-Line: Pharmacologic Therapy

For patients who decline ablation or are not candidates:

Preferred agents (Class I):

• Oral beta-blockers, diltiazem, or verapamil for patients without ventricular pre-excitation 2
• These are the only agents that are NOT significantly proarrhythmogenic 6

Alternative agents (Class IIa):

• Flecainide or propafenone ONLY in patients without structural heart disease or ischemic heart disease 2

Major downgrades—avoid these agents:

• Amiodarone, sotalol, and digoxin have been downgraded or removed from recommendations 1
• The "pill-in-the-pocket" approach is no longer recommended 1
• Most antiarrhythmic drugs are proarrhythmogenic and should be avoided 6

Critical Pitfalls to Avoid

1. Do not use calcium channel blockers or digoxin in wide-QRS tachycardia until ventricular tachycardia is excluded—this can be fatal in pre-excited atrial fibrillation
2. Do not start with 6 mg adenosine—recent data supports 12 mg as initial dose 4
3. Do not continue long-term antiarrhythmic drugs when ablation is available—success rates favor ablation and avoid drug toxicity 1, 3
4. Document vagal maneuver attempts—only 26% of cases have documented attempts despite Class I recommendation 4
5. All antiarrhythmic drugs must be avoided in first trimester pregnancy; catheter ablation with radiation-free techniques is now preferred for refractory cases 6

Patient Education

Teach all patients how to perform vagal maneuvers for self-management of recurrent episodes (Class I) 2.

Referral Pathway

All patients treated for SVT should be referred to a heart rhythm specialist for consideration of definitive ablation therapy 7.